The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences
Open accessAbstract
The introduction of atypical antipsychotics (AAPs) since the discovery of its prototypical drug clozapine has been a revolutionary pharmacological step for treating psychotic patients as these allow a significant recovery not only in terms of hospitalization and reduction in symptoms severity, but also in terms of safety, socialization and better rehabilitation in the society. Regarding the mechanism of action, AAPs are weak D2 receptor antagonists and they act beyond D2 antagonism, involving other receptor targets which regulate dopamine and other neurotransmitters. Consequently, AAPs present a significant reduction of deleterious side effects like parkinsonism, hyperprolactinemia, apathy and anhedonia, which are all linked to the strong blockade of D2 receptors. This review revisits previous and current findings within the class of AAPs and highlights the differences in terms of receptor properties and clinical activities among them. Furthermore, we propose a continuum spectrum of “atypia” that begins with risperidone (the least atypical) to clozapine (the most atypical), while all the other AAPs fall within the extremes of this spectrum. Clozapine is still considered the gold standard in refractory schizophrenia and in psychoses present in Parkinson's disease, though it has been associated with adverse effects like agranulocytosis (0.7%) and weight gain, pushing the scientific community to find new drugs as effective as clozapine, but devoid of its side effects. To achieve this, it is therefore imperative to characterize and compare in depth the very complex molecular profile of AAPs. We also introduce relatively new concepts like biased agonism, receptor dimerization and neurogenesis to identify better the old and new hallmarks of “atypia”. Finally, a detailed confrontation of clinical differences among the AAPs is presented, especially in relation to their molecular targets, and new means like therapeutic drug monitoring are also proposed to improve the effectiveness of AAPs in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Neurotrophins: Roles in Neuronal Development and Function
Huang, E. J., & Reichardt, L. F. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.677 · Cited by 4,394
Dopamine receptors: from structure to function
MISSALE, C., NASH, S. R., ROBINSON, S. W., JABER, M., & CARON, M. G. (1998) · Physiological Reviews · doi:10.1152/physrev.1998.78.1.189 · Cited by 3,633
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.013 · Cited by 1,742
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Breier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Moghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Identification of a serotonin/glutamate receptor complex implicated in psychosis
González-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., López-Giménez, J. F., Zhou, M., Okawa, Y., Callado, L. F., Milligan, G., et al. (2008) · Nature · doi:10.1038/nature06612 · Cited by 803
Human prefrontal cortex: processing and representational perspectives
Wood, J. N., & Grafman, J. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1033 · Cited by 721
Glutamate and dopamine in schizophrenia: An update for the 21 st century
Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702
Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development
Wess, J., Eglen, R. M., & Gautam, D. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2379 · Cited by 637
Bias factor and therapeutic window correlate to predict safer opioid analgesics
Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., Cameron, M. D., Bannister, T. D., & Bohn, L. M. (2017) · Cell · doi:10.1016/j.cell.2017.10.035 · Cited by 567
Leucht, S., Leucht, C., Huhn, M., Chaimani, A., Mavridis, D., Helfer, B., Samara, M., Rabaioli, M., Bächer, S., Cipriani, A., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16121358 · Cited by 542
Tseng, K. Y., & O'Donnell, P. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1021-04.2004 · Cited by 402
Amargos-Bosch, M. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhg128 · Cited by 370
Merritt, K., Egerton, A., Kempton, M. J., Taylor, M. J., & McGuire, P. K. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0442 · Cited by 367
Keefe, R. S. E., Seidman, L. J., Christensen, B. K., Hamer, R. M., Sharma, T., Sitskoorn, M. M., Lewine, R. R. J., Yurgelun-Todd, D. A., Gur, R. C., Tohen, M., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.985 · Cited by 314
Fribourg, M., Moreno, J. L., Holloway, T., Provasi, D., Baki, L., Mahajan, R., Park, G., Adney, S. K., Hatcher, C., Eltit, J. M., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.055 · Cited by 311
Schizophrenia: More dopamine, more D 2 receptors
Seeman, P., & Kapur, S. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.7673 · Cited by 279
Curtis, J., Watkins, A., Rosenbaum, S., Teasdale, S., Kalucy, M., Samaras, K., & Ward, P. B. (2016) · Early Intervention in Psychiatry · doi:10.1111/eip.12230 · Cited by 227
Sykes, D. A., Moore, H., Stott, L., Holliday, N., Javitch, J. A., Lane, J. R., & Charlton, S. J. (2017) · Nature Communications · doi:10.1038/s41467-017-00716-z · Cited by 218
The NMDA receptor ‘glycine modulatory site’ in schizophrenia: d-serine, glycine, and beyond
Balu, D. T., & Coyle, J. T. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.12.004 · Cited by 208
Imaging glutamate in schizophrenia: review of findings and implications for drug discovery
Poels, E. M. P., Kegeles, L. S., Kantrowitz, J. T., Slifstein, M., Javitt, D. C., Lieberman, J. A., Abi-Dargham, A., & Girgis, R. R. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.136 · Cited by 205
Bymaster, F. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00146-7 · Cited by 200
López-Gil, X., Babot, Z., Amargós-Bosch, M., Suñol, C., Artigas, F., & Adell, A. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301356 · Cited by 183
Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study
Jauhar, S., Veronese, M., Nour, M. M., Rogdaki, M., Hathway, P., Turkheimer, F. E., Stone, J., Egerton, A., McGuire, P., Kapur, S., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0042-4 · Cited by 183
The Fibroblast Growth Factor Family: Neuromodulation of Affective Behavior
Turner, C. A., Watson, S. J., & Akil, H. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.037 · Cited by 160
Estimating Dopamine D2 Receptor Occupancy for Doses of 8 Antipsychotics: A Meta-Analysis
Lako, I. M., van den Heuvel, E. R., Knegtering, H., Bruggeman, R., & Taxis, K. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182983ffa · Cited by 125
Dopamine D2 and D4 receptor heteromerization and its allosteric receptor–receptor interactions
Borroto-Escuela, D. O., Craenenbroeck, K. V., Romero-Fernandez, W., Guidolin, D., Woods, A. S., Rivera, A., Haegeman, G., Agnati, L. F., Tarakanov, A. O., & Fuxe, K. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.12.083 · Cited by 98
Uchida, H., Takeuchi, H., Graff-Guerrero, A., Suzuki, T., Watanabe, K., & Mamo, D. C. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318218d339 · Cited by 94
Elucidation of G-protein and β-arrestin functional selectivity at the dopamine D2 receptor
Peterson, S. M., Pack, T. F., Wilkins, A. D., Urs, N. M., Urban, D. J., Bass, C. E., Lichtarge, O., & Caron, M. G. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502742112 · Cited by 91
Morais, M., Patrício, P., Mateus-Pinheiro, A., Alves, N. D., Machado-Santos, A. R., Correia, J. S., Pereira, J., Pinto, L., Sousa, N., & Bessa, J. M. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.120 · Cited by 56
G Protein-Coupled Receptor Heterocomplexes in Neuropsychiatric Disorders
Moreno, J. L., Holloway, T., & González-Maeso, J. (2013) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-386931-9.00008-8 · Cited by 30
Cited by
Current Concepts and Treatments of Schizophrenia
Stępnicki, P., Kondej, M., & Kaczor, A. A. (2018) · Molecules · doi:10.3390/molecules23082087 · Cited by 556
Dopamine, Immunity, and Disease
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 308
The impact of sugar consumption on stress driven, emotional and addictive behaviors
Jacques, A., Chaaya, N., Beecher, K., Ali, S. A., Belmer, A., & Bartlett, S. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.05.021 · Cited by 271
Nazarova, V. A., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1066988 · Cited by 111
Das, D., Peng, X., Lam, A.-T. N., Bader, J. S., & Avramopoulos, D. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2020.12.041 · Cited by 17
Metadata
- Authors
- Aringhieri, S., Carli, M., Kolachalam, S., Verdesca, V., Cini, E., Rossi, M., McCormick, P. J., Corsini, G. U., Maggio, R., & Scarselli, M.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 192
- Pages
- 20-41
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2809761645
- Cited by
- 199
- References
- 36
- FWCI
- 13.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.